Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy

被引：0
|
作者：
Chi Yan
Ann Richmond
机构：
[1] Tennessee Valley Healthcare System,Department of Pharmacology
[2] Department of Veterans Affairs,undefined
[3] Vanderbilt University School of Medicine,undefined
来源：
Molecular Cancer | / 20卷
关键词：
CD40; Cancer; Nevi; Melanoma; PD-1/PD-L1; CTLA4; Targeted therapy; Immune therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
    David Digomann
    Max Heiduk
    Charlotte Reiche
    Jessica Glück
    Christoph Kahlert
    Peter Mirtschink
    Anna Klimova
    Florian Bösch
    Torsten Tonn
    Jochen Gaedcke
    Michael Ghadimi
    Jürgen Weitz
    Lena Seifert
    Adrian M. Seifert
    npj Precision Oncology, 7
  • [22] Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
    Digomann, David
    Heiduk, Max
    Reiche, Charlotte
    Glueck, Jessica
    Kahlert, Christoph
    Mirtschink, Peter
    Klimova, Anna
    Boesch, Florian
    Tonn, Torsten
    Gaedcke, Jochen
    Ghadimi, Michael
    Weitz, Juergen
    Seifert, Lena
    Seifert, Adrian M.
    NPJ PRECISION ONCOLOGY, 2023, 7 (01)
  • [23] A pan-cancer analysis of MUC family genes as potential biomarkers for immune checkpoint therapy.
    Li, Yang
    Duan, Qianqian
    Tan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Agonistic CD40 antibody therapy induces formation of tertiary lymphoid structures in glioma and inhibits the response to immune-checkpoint blockade
    van Hooren, Luuk
    Vaccaro, Alessandra
    Georganaki, Maria
    Ramachandran, Mohanraj
    Huang, Hua
    Lau, Joey
    Smits, Anja
    Essand, Magnus
    Dimberg, Anna
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [25] Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
    Yoshihiro Kitahara
    Yusuke Inoue
    Hideki Yasui
    Masato Karayama
    Yuzo Suzuki
    Hironao Hozumi
    Kazuki Furuhashi
    Noriyuki Enomoto
    Tomoyuki Fujisawa
    Kazuhito Funai
    Tetsuya Honda
    Kiyoshi Misawa
    Hideaki Miyake
    Hiroya Takeuchi
    Naoki Inui
    Takafumi Suda
    Respiratory Research, 25
  • [26] Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
    Kitahara, Yoshihiro
    Inoue, Yusuke
    Yasui, Hideki
    Karayama, Masato
    Suzuki, Yuzo
    Hozumi, Hironao
    Furuhashi, Kazuki
    Enomoto, Noriyuki
    Fujisawa, Tomoyuki
    Funai, Kazuhito
    Honda, Tetsuya
    Misawa, Kiyoshi
    Miyake, Hideaki
    Takeuchi, Hiroya
    Inui, Naoki
    Suda, Takafumi
    RESPIRATORY RESEARCH, 2024, 25 (01)
  • [27] A pan-cancer analysis of KMT2D as a potential biomarker for immune checkpoint therapy
    Guan, X.
    Cai, S.
    Wu, X.
    Chen, Y.
    Deng, H.
    Zhong, X.
    Chen, T.
    Huang, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S847 - S847
  • [28] A pan-cancer analysis of ARID1A as a potential biomarker for immune checkpoint therapy.
    Yang, Dongyong
    Xu, Yuan
    Huang, Linlin
    Guo, Zhifeng
    Fan, Jimin
    Chen, Tingting
    Xie, Wenzhuan
    Huang, Mengli
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy
    Zhu, Yan
    Yan, Chun
    Wang, Xiaofei
    Xu, Zhijian
    Lv, Jianjian
    Xu, Xiaomei
    Yu, Wenjun
    Zhou, Mi
    Yue, Lu
    CANCER BIOLOGY & THERAPY, 2022, 23 (01) : 104 - 111
  • [30] A pan-cancer analysis of GRIN2A as a potential biomarker for immune checkpoint therapy.
    Jiang, Mei
    Zhong, Xuefeng
    Huang, Mengli
    CANCER RESEARCH, 2022, 82 (12)
12345